AI in drug discovery: do you know the value of your healthcare data?
Artificial intelligence (AI) can be an umbrella term used to describe technologies that can mimic traits associated with the human mind. These technologies can learn from experience and can be trained to accomplish specific tasks (such as problem-solving) by processing large amounts of data and recognising patterns in the data.
With AI-driven research into new drugs, how can this data be protected and how can value be extracted? Claire Smith, Adam Coughlin and Alex Magnusdottir discuss
Sophie Lawrance interviewed by Financier Worldwide on best practice in licensing disputes
Head of Bristows’ Brands, Designs and Copyright practice named an Appointed Person for trade mark appeals from the UKIPO
Fiona Nicolson appointed President of LESI, the global intellectual property organisation
Bristows’ Commercial and IP Transactions practice gains new partner with promotion of Claire Smith